Halozyme’s Spotlight Shifts To Enhanze Exclusively After PEGPH20 Fails In Phase III
Executive Summary
The Enhanze drug delivery technology, which is expected to be profitable starting next year, takes center stage as Halozyme discontinues PEGPH20 development and cuts its oncology operations along with 160 jobs.
You may also be interested in...
Genentech’s Subcutaneous Tecentriq Shows Non-Inferiority To I.V. Formulation
The Roche affiliate hopes to bring subcutaneous Tecentriq to market, offering patient and clinician advantages while also beating Merck’s Keytruda and Bristol’s Opdivo to the finish line
Halozyme Buys Antares, Expanding Drug Delivery Ambitions
Halozyme will pay $960m to acquire Antares, gaining an auto-injector drug delivery platform, which the company said has broad licensing potential, as well as a commercial portfolio.
Halozyme Buys Antares, Expanding Drug Delivery Ambitions
Halozyme will pay $960m to acquire Antares, gaining an auto-injector drug delivery platform, which the company said has broad licensing potential, as well as a commercial portfolio.